Eupraxia Sees 65% EREFS Reduction with 20 Injections in Phase 1b/2a Trial
Eupraxia’s Phase 1b/2a RESOLVE trial showed a mean 65% EREFS reduction (3.6 points) at week 12 for patients receiving 20 EP-104GI injections, with near-complete scores in the 20×6mg and 20×8mg cohorts. These dose-dependent improvements underpin the 20-injection regimen chosen for the Phase 2b trial with 120mg and 160mg arms.
1. Dose-dependent EREFS improvements
The RESOLVE trial’s Phase 1b/2a data demonstrated that patients receiving the full 20 injections of EP-104GI achieved a mean 65% reduction in EREFS (3.6 points) at week 12, compared with smaller protocols. Of the seven patients with baseline scores above 2, those in the 20×6mg and 20×8mg cohorts (n=4) showed near-complete normalization of endoscopic findings.
2. Inflammatory and fibrotic subscore gains
Beyond overall EREFS, higher-dose cohorts exhibited consistent improvements in both inflammatory and fibrotic subscores, suggesting EP-104GI’s potential to reduce edema, rings, strictures and other hallmarks of eosinophilic esophagitis. The concordant response across these domains supports the treatment’s multifaceted efficacy.
3. Phase 2b trial design and timeline
Based on these Phase 1b/2a results, Eupraxia elected a 20-injection pattern for its placebo-controlled Phase 2b study, now recruiting 120mg (20×6mg) and 160mg (20×8mg) dosing arms. Top-line data from this randomized trial are anticipated in Q4 2026 to confirm efficacy and inform potential regulatory pathways.